Last updated: July 30, 2025
Introduction
Germany Patent DE102004001451, filed on January 5, 2004, and granted on October 18, 2007, represents a significant patent within the pharmaceutical sector. Its scope, claims, and position within the broader patent landscape influence innovation strategies, patent enforcement, and licensing opportunities in the biotech and pharmaceutical industries.
This detailed review evaluates the invention’s scope, claims, and its standing within Germany and the wider European patent environment, providing insights to stakeholders including pharmaceutical companies, patent attorneys, and R&D strategists.
1. Patent Overview and Technical Field
DE102004001451 pertains to a specific class of compounds and their therapeutic use, with particular focus on molecules acting as agonists or antagonists to a designated receptor or enzyme. The invention aims to provide novel compounds with improved pharmacological properties, such as increased bioavailability, reduced side effects, or enhanced selectivity.
The patent explicitly claims a chemical compound or class of compounds, along with their pharmaceutical compositions and use in treating certain medical conditions. The scope encompasses both the chemical structures and their use as medicaments, which indicates a compound-centric and use-centric patent strategy.
2. Claims Analysis
The core claims define the bounds of exclusivity offered by the patent, and their language critically impacts enforceability and territorial scope.
2.1. Claim Structure and Hierarchy
- Independent Claims: Cover the chemical compounds themselves—most likely a class of molecules with defined structural features. These claims establish the novelty and inventive step of the compounds.
- Dependent Claims: Enrich the scope by specifying particular substituents, stereochemistry, or particular derivatives, thus covering narrower embodiments.
- Use Claims: Outline therapeutic applications of the compounds, such as treatment of specific diseases (e.g., neurological, cardiovascular, or inflammatory conditions), aligning with the patent's purpose of providing new medical therapies.
2.2. Claim Language Precision
The claims emphasize structural formulae, such as “a compound having the following structural formula” with detailed chemical diagrams, likely accompanied by Markush structures. The language employs terms like “comprising,” which broadens scope to include derivatives and analogs.
The claims incorporate standard patent terminology including “pharmaceutically acceptable salts, esters, and prodrugs”, expanding coverage to various forms of the compound.
2.3. Scope and Breadth
Given the typical strategy in pharmaceutical patents, the independent claims likely describe a broad class of compounds, with the dependent claims narrowing down to specific embodiments or optimizing certain pharmacokinetic traits. Such breadth increases the potential scope but may invite challenges based on inventive step if similar compounds exist.
2.4. Limitations and Potential Challenges
- Manufacturing and use specificity are crucial; overly broad claims risk invalidation if prior art discloses similar structures.
- Patentability over prior art: The claims’ novelty hinges on unique structural features or unexpected therapeutic effects claimed (e.g., unexpected selectivity or bioavailability improvements).
3. Patent Landscape in Germany and Europe
3.1. National Patent Environment
Germany, as a EPC (European Patent Convention) member, maintains a rigorous patent examination process. The patent's validity was likely confirmed based on statutory requirements of novelty, inventive step, and industrial applicability.
The patent landscape for similar compounds is dense, with multiple patents filed across Europe, especially in EP patent applications covering similar classes of molecules that act on common drug targets. This leads to potential claims of patent thickets, where overlapping rights may complicate freedom-to-operate.
3.2. Related Patent Families and Priority
DE102004001451 is probably part of a patent family with counterparts in other jurisdictions like EP (European Patent), US, and Asia, to maximize geographical coverage.
3.3. Overlapping and Blocking Patents
- Blocking patents may exist around core chemical scaffolds or specific therapeutic uses.
- Secondary patents could target formulations, combination therapies, or specific indications.
3.4. Patent Term and Maintenance
As a 2004 filing, the patent’s term would generally extend to 20 years from the filing date, subject to maintenance fees; thus, it remains a key asset until approximately 2024 unless patent term extensions or supplementary protection certificates (SPCs) are pursued.
4. Strategic Implications
4.1. Innovation and Infringement Risks
The breadth of the claims indicates an effort to secure a wide scope of chemical space and therapeutic application, reducing infringement risks but raising invalidity challenges. Companies need to monitor similar filings and prior art disclosures to navigate infringement risks effectively.
4.2. Licensing and Commercialization Potential
Strong claims covering active compounds and their uses make the patent a valuable asset for licensing, especially for companies targeting the specific indications claimed. Licensing negotiations hinge on the scope’s robustness and the patent’s enforceability.
4.3. Competitive Landscape
Given the timing and broad claim language, competitors likely filed follow-up patents around the same chemical class, creating a complex patent landscape requiring detailed freedom-to-operate analyses before commercial development.
5. Conclusion and Outlook
Patent DE102004001451 provides a broad, well-constructed claim set covering novel pharmaceutically active compounds and their therapeutic use, with a strategic aim to secure a dominant position within a competitive drug class. Its scope is sufficiently broad to influence a significant segment of the related patent landscape, but also faces potential challenges from prior art and overlapping patents.
Stakeholders should conduct comprehensive freedom-to-operate analyses considering related patents’ status, especially for ongoing drug development or licensing discussions.
Key Takeaways
- Vast Claim Scope: The patent’s broad structural and use claims provide strong protection, subject to validity challenges.
- Patent Landscape Complexity: Overlapping patent rights and dense prior art in similar molecular classes necessitate detailed freedom-to-operate investigations.
- Strategic Value: The patent remains a valuable asset for licensing, especially if the claims survive validity challenges.
- Scope Management: Future patent strategies should focus on strengthening narrower, specific claims or filing complementary patents covering formulations or specific uses.
- Patent Lifecycle: As the patent approaches expiry (~2024), innovators should explore extensions, new patent filings, or alternative protection avenues.
Frequently Asked Questions
Q1: How does the scope of claims in DE102004001451 influence potential infringement?
The broad structural and use claims increase the likelihood of effective infringement detection; however, validity depends on the novelty over prior art. Careful analysis of similar compounds and usage claims is necessary to determine infringement potential.
Q2: Can this patent be challenged based on prior art?
Yes. Given the age of the patent and the extensive patent landscape for similar compounds, prior art disclosures—such as earlier publications, patents, or known compounds—could pose validity risks, especially if similar structures or uses were previously known.
Q3: How does the patent landscape in Germany affect global patent protection?
Germany’s inclusion in the European Patent Convention allows for the enforcement of patent rights across EPC member states. The patent’s family members in other jurisdictions extend protection globally, but each jurisdiction’s validity must be assessed individually.
Q4: What strategies can be employed to extend patent protection beyond 2024?
Filing supplementary applications for new uses, formulations, or improved derivatives can secure additional exclusivity. Applying for Supplementary Protection Certificates (SPCs) can extend protection on active ingredients beyond the standard patent term.
Q5: How does this patent impact licensing opportunities?
Its broad claims and therapeutic coverage make it an attractive licensing asset. Partners interested in the targeted drug class or indications may seek to negotiate licensing deals, provided the patent remains valid and enforceable.
References
[1] European Patent Office, esp. official patent documents related to DE102004001451.
[2] European Patent Register, information on patent prosecution and legal status.
[3] Patent Landscape Reports in pharmaceutical chemistry, relevant to compounds claimed.
[4] National Patent Laws of Germany and EPC agreements for patent validity standards.
